Loading clinical trials...
Loading clinical trials...
An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)
Conditions
Interventions
Oxaliplatin, Capecitabine, Panitumumab
Oxaliplatin, Capecitabine
Locations
1
Germany
AIO-Studien-gGmbH
Berlin, State of Berlin, Germany
Start Date
September 1, 2009
Primary Completion Date
November 1, 2011
Completion Date
March 1, 2012
Last Updated
March 4, 2013
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
AIO-Studien-gGmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions